Compare HTZ & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | IMNM |
|---|---|---|
| Founded | 1918 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1997 | 2020 |
| Metric | HTZ | IMNM |
|---|---|---|
| Price | $5.46 | $20.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.05 | ★ $26.89 |
| AVG Volume (30 Days) | ★ 8.5M | 1.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,516,000,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.15 | $5.15 |
| 52 Week High | $9.39 | $20.46 |
| Indicator | HTZ | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.29 | 65.02 |
| Support Level | $5.03 | $18.87 |
| Resistance Level | $5.68 | $20.46 |
| Average True Range (ATR) | 0.25 | 1.22 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 79.20 | 95.49 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.